ERBB2 and colorectal carcinoma: Feng et al. [30], showed that HER2 overexpression in 206 patients was associated with better OS and risk-free survival (RFS) in those who received chemotherapy vs. those who did not, while in another retrospective analysis of 1914 CRC-II samples found that HER2 expression was not associated with OS and recurrence [31].